TABLE 3.
IHC in primary lung carcinoma; ALK, ROS1, PD‐L1 assessment and molecular profiling in advanced NSCLC CB with respective final cytological diagnosis
| NSCLC + SCLC patients | 245 | |
|---|---|---|
| IHC tests done | 133 | |
| Advanced stage NSCLC (IIIb + IV) | 164/196 | 83.6% |
| Advanced NSCLC, Adenocarcinoma type | 146 | 96% |
| Adequate for ALK, ROS, PD‐L1 IHC profiling | 140 | 96% |
| Inadequate for ALK, ROS, PD‐L1 IHC profiling | 6 | 4% |
| Adequate for molecular profiling | 137 | 93.8% |
| Indequate for molecular profiling | 9 | 6.2% |
| Advanced NSCLC, squamous cell type | 16 | |
| Adequate for PDL1 IHC profiling | 13 | 81% |
| Advanced NSCLC, NOS type | 2 | |
| Adequate for ALK, ROS, PD‐L1 IHC profiling | 2 | 100% |
| Adequate for molecular profiling | 2 | 100% |
Abbreviations: ALK, anaplastic lymphoma kinase; IHC, immunohistochemistry; NOS, not otherwise specified; NSCLC, non‐small cell lung cancer; PD‐L1, programmed cell‐death ligand 1; ROS1, ROS proto‐oncogene 1; SCLC, small cell lung cancer.